关键词: 可切除胰腺癌, 新辅助治疗

Abstract:

Value and evaluation neoadjuvant therapy in pancreatic cancer        LIANG Ting-bo，BAI Xue-li，LI Xiang. Department of Hepatobiliary and Pancreatic Surgery，the Second Affiliated Hospital，Zhejiang University School of Medicine，Hangzhou 310009，China
Corresponding author：LIANG Ting-bo，E-mail：liangtingbo@
zju.edu.cn
Abstract    Recently，accumulative evidence demonstrates that patients with non-metastatic pancreatic cancer can benefit from neoadjuvant therapy. Hence the application of neoadjuvant in pancreatic cancer patients became a hot topic and been paid much more attention than ever. Surgery is considered as the only curable method for resectable pancreatic cancer（RPC） traditionally，and the application of neoadjuvant therapy in RPC remains controversial. According to the data from previous studies，neoadjuvant therapy did not prolong the survival of RPC. However，with the development of chemotherapy regimens，more and more promising results were obtained from retrospective and prospective research in recent years. Much more high-level clinical trials are still required to confirm whether neoadjuvant therapy is mandatory for all RPC patients.

Key words: resectable pancreatic adenocarcinoma, neoadjuvant therapy